Article ; Online: Melatonin Enhances Anti-tumoral Effects of Menadione on Colon Cancer Cells.
Anti-cancer agents in medicinal chemistry
2021 Volume 22, Issue 13, Page(s) 2411–2418
Abstract: Background: Colon cancer is one of the most important causes of death in the entire world. New pharmacological strategies are always needed, especially in resistant variants of this pathology. We have previously reported that drugs such as menadione ( ... ...
| Abstract | Background: Colon cancer is one of the most important causes of death in the entire world. New pharmacological strategies are always needed, especially in resistant variants of this pathology. We have previously reported that drugs such as menadione (MEN), D, L-buthionine-S,R-sulfoximine or calcitriol, used in combination, enhanced cell sensibility of breast and colon tumour models, due to their ability to modify the oxidative status of the cells. Melatonin (MEL), a hormone regulating circadian rhythms, has anti-oxidant and anti-apoptotic properties at low concentrations, while at high doses, it has been shown to inhibit cancer cell growth. Objective: The objective of this study is to determine the antitumoral action of the combination MEN and MEL on colon cancer cells. Methods: Caco-2 cells were employed to evaluate the effects of both compounds, used alone or combined, on cellular growth/morphology, oxidative and nitrosative stress, and cell migration. Results: MEN plus MEL dramatically reduced cell proliferation in a time and dose-dependent manner. The antiproliferative effects began at 48 h. At the same time, the combination modified the content of superoxide anion, induced the formation of reactive nitrogen species and enhanced catalase activity. Cell migration process was delayed. Also, changes in nuclear morphology consistent with cell death were observed. Conclusion: The enhanced effect of simultaneous use of MEN and MEL on Caco-2 cells suggests that this combined action may have therapeutic potential as an adjuvant on intestinal cancer acting in different oncogenic pathways. |
|---|---|
| MeSH term(s) | Antioxidants/metabolism ; Antioxidants/pharmacology ; Buthionine Sulfoximine/pharmacology ; Caco-2 Cells ; Colonic Neoplasms/drug therapy ; Humans ; Melatonin/pharmacology ; Oxidative Stress ; Vitamin K 3/pharmacology |
| Chemical Substances | Antioxidants ; Buthionine Sulfoximine (5072-26-4) ; Vitamin K 3 (723JX6CXY5) ; Melatonin (JL5DK93RCL) |
| Language | English |
| Publishing date | 2021-12-06 |
| Publishing country | Netherlands |
| Document type | Journal Article ; Research Support, Non-U.S. Gov't |
| ZDB-ID | 2217610-X |
| ISSN | 1875-5992 ; 1871-5206 |
| ISSN (online) | 1875-5992 |
| ISSN | 1871-5206 |
| DOI | 10.2174/1871520621666211207141729 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.A 5583: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.